| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Travere Therapeutics, Inc. (TVTX) has 16 insiders with recent SEC Form 4 filings, including 0 buys and 12 sells. TVTX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 440.1K | $19.61M | -64,000 | |
| Other | 138.6K | $6.17M | - | |
| Other | 123.1K | $5.48M | - | |
| CFO | 116.9K | $5.21M | -1,014 | |
| Other | 111.5K | $4.97M | -1,018 |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 1, 2024 | Calvin Sandra60 | SVP, Chief Accounting Officer | Sell | 2,820 | $8.53 | $24,057.98 | -5.1% | -30.2% | +137.9% | |
| Feb 1, 2024 | Reed Elizabeth E58 | SVP, GC &Corporate Secretary | Sell | 4,764 | $8.71 | $41,495.32 | -3.0% | -30.2% | +137.9% | |
| Feb 1, 2024 | Heerma Peter53 | Chief Commercial Officer | Sell | 4,195 | $8.53 | $35,788.80 | -4.0% | -30.2% | +137.9% | |
| Feb 1, 2024 | Inrig Jula45 | Chief Medical Officer | Sell | 2,174 | $8.53 | $18,546.61 | -3.6% | -30.2% | +137.9% | |
| Feb 1, 2024 | Cline Christopher R.50 | Chief Financial Officer | Sell | 3,818 | $8.53 | $32,572.50 | -5.1% | -30.2% | +137.9% | |
| Feb 1, 2024 | Dube Eric M57 | Chief Executive Officer | Sell | 19,122 | $8.70 | $166,435.06 | -2.6% | -30.2% | +137.9% | |
| Jan 23, 2024 | Reed Elizabeth E58 | SVP, GC &Corporate Secretary | Sell | 2,062 | $8.96 | $18,475.52 | -3.5% | -37.0% | +109.5% | |
| Jan 23, 2024 | Dube Eric M57 | Chief Executive Officer | Sell | 7,873 | $8.96 | $70,542.08 | -3.2% | -37.0% | +109.5% | |
| Jan 23, 2024 | Cline Christopher R.50 | Chief Financial Officer | Sell | 853 | $9.07 | $7,735.35 | -1.7% | -37.0% | +109.5% | |
| Jan 23, 2024 | Rote William E.58 | Senior Vice President, R&D | Sell | 2,062 | $8.96 | $18,475.52 | -3.3% | -37.0% | +109.5% |